Baseline Characteristics

Baseline characteristics of patients (January 1, 2008 – September 15, 2026)

Total cohort: 38,399 patients. This table uses a different cohort count and reporting period from the Data at a Glance summary.
Baseline characteristics of 38,399 patients, January 1, 2008 – September 15, 2026
VariablesTotal
Total patients38,399
Age at diagnosis
< 65y19,931 (51.9%)
≥ 65y18,468 (48.1%)
Smoking status (missing=118 (0.3%))
Never16,719 (43.5%)
Former/Current21,562 (56.2%)
Histology
Non-adenocarcinoma9,444 (24.6%)
Adenocarcinoma28,955 (75.4%)
Clinical stage (missing=82 (0.2%))
I17,375 (45.2%)
II3,649 (9.5%)
III5,300 (13.8%)
IV11,993 (31.2%)
Pathologic stagen=22,811
I15,424 (40.2%)
II3,452 (9.0%)
III3,075 (8.0%)
IV581 (1.5%)
EGFR mutationn=32,992
No Mutation19,113 (57.9%)
Mutation13,773 (41.7%)
Not assessed106 (0.3%)
Del19 (L858R combine)6,379(10) (19.3%-all/ 46.3%-Mut)
L858R (del19 combine)5,814(10) (17.6%-all/ 42.2%-Mut)
Others (G719X, S768I, POL20, INS20…)1,590 (4.8%)
ALK arrangementn=32,649
Negative31,375 (96.1%)
Positive1,119 (3.4%)
Not assessed155 (0.5%)
PD-L1 (22C3, TPS)n=22,383 (positive=6)
≥50%4,636 (12.1%)
1–49%5,588 (14.6%)
<1%12,131 (31.6%)
Not assessed22 (0.1%)
Curative intent surgery
Yes (+neo adj after OP)20,501 (53.4%)
Definitive CCRT
Yes1,932 (5.0%)
First line-palliative regimen11,993 (31.2%)
First line-EGFR TKI containing regimen3,428 (8.9%)
First line-ALK TKI containing regimen495 (1.3%)
First line-IO containing regimen1,822 (4.7%)
Second line-palliative regimen7,543 (19.6%)
Third line-palliative regimen4,095 (10.7%)
Others (RT only, GKS only, wedge OP, etc..)3,973 (10.3%)
NGS; Total number of NGS tests
(Multiple tests per patient were counted separately)
6,094 (15.9%)
Liquid NGS1,414 (23.2%)
Tissue NGS4,457 (73.1%)
Death16,330 (42.5%)
Alive (n=106 (0.3%) Death status to be confirmed)21,963 (57.2%)

Footnotes

  • Data are presented as n (%). EGFR exon 19 deletion and L858R percentages are shown among tested and mutation-positive patients; 10 patients with both mutations are included in both groups. ALK low expression was classified as negative. NA indicates an unavailable or uninterpretable test result. PD-L1 (22C3) is reported as TPS.
  • TNM reference implementation years: seventh edition, 2010; eighth edition, 2017 internationally (AJCC, 2018); AJCC Version 9, 2025. Institutional adoption dates were not confirmed.
  • Clinical and pathological stage percentages were calculated using the total cohort (N=38,399), including patients with missing stage data.
  • Pathologic stage includes patients who underwent surgery after neo-adjuvant therapy.
  • First-line EGFR/ALK TKI regimens are included in the first-line palliative treatment category. “Others” includes patients treated at SMC who did not meet the definitions of curative-intent surgery, definitive CCRT, or first-line palliative treatment.

Abbreviations

AJCC, American Joint Committee on Cancer; ALK, anaplastic lymphoma kinase; CCRT, concurrent chemo-radiotherapy; EGFR, epidermal growth factor receptor; NGS, next-generation sequencing; NSCLC, non-small cell lung cancer; PCR, polymerase chain reaction; PD-L1, programmed death-ligand 1; TKI, tyrosine kinase inhibitor; TNM, tumor–node–metastasis; TPS, tumor proportion score; WT, wild type.

Back to Data